Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial (Q42706199)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 27 March 2014

Language	Label	Description	Also known as
English	Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial	scientific article published on 27 March 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

phase III clinical trial

0 references

0 references

1 reference

ChEBI release 2020-05-28

0 references

author name string

David Michelson

1

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Ellen Snyder

2

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Erin Paradis

3

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Mary Chengan-Liu

4

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Duane B Snavely

5

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Jill Hutzelmann

6

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

James K Walsh

7

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Andrew D Krystal

8

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Ruth M Benca

9

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Martin Cohn

10

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Christopher Lines

11

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Thomas Roth

12

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

W Joseph Herring

13

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

publication date

27 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

461-471

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Chronic insomnia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter stu

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Insomnia pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The orexin system: roles in sleep/wake regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Orexin receptors as therapeutic drug targets

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The Benzodiazepine Withdrawal Symptom Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the Insomnia Severity Index as an outcome measure for insomnia research

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Etrank: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypocretin (orexin) deficiency in human narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970053-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(14)70053-5

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42706199&oldid=2207680441"